Return to homepagePandemic Pact

Step down of asthma biologics in real-world practice settings

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3R21HL140287-02S1

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $21,370

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    Matthew A Rank

  • Research Location

    United States of America

  • Lead Research Institution

    Mayo Clinic Arizona

  • Research Priority Alignment

    N/A

  • Research Category

    Epidemiological studies

  • Research Subcategory

    Disease susceptibility

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Our overall goal is to identify risk factors in people with asthma for being hospitalized for COVID-19. Our teamis uniquely positioned to quickly analyze pre-existing data that includes risk factors likely to be relevant forpeople with asthma who are hospitalized for COVID-19. Our team has used a claims data set that includes200+ million people residing in the US in multiple studies in people with asthma called OptumLabs DatabaseWarehouse (OLDW).We hypothesize that there are behavior, health care delivery, and patient demographic factors associated withhospitalization for COVID-19 in people with asthma. To test this hypothesis, we will analyze pre-existing datafrom OLDW, testing the following independent variables: age, sex, race-ethnicity, smoking, comorbid chronicdiseases, geographic region, rural/urban residence, access to provider care (traditional and telehealth),medication-filling behavior, and types of asthma medications filled.